Peldesine
Peldesine 用途与合成方法
IC50: 36 nM (Human RBC PNP), 5 nM (Rat RBC PNP), 32 nM (Mouse RBC PNP), and 800 nM (Human T-cell proliferation)
Ki: 23 nM (Human RBC PNP)
HIV
Peldesine (BCX 34; 0-50 µM; 72 hours; Jurkat cells) could inhibit the T-cell proliferation completely at a concentration of less than 10 μM, in the presence of dGuo (10 μM). In contrast, the B-cell proliferation is not affected by Peldesine.
Peldesine (BCX 34) suppresses T-cell immune reaction in an IL-2-independent manner, and this means that Peldesine might affect a late phase rather than an early stage in T-cell activation.
Peldesine also, in the presence but not in the absence of deoxyguanosine, inhibits human leukemia CCRF-CEM T-cell proliferation with an IC
50
of 0.57 μM but not rat or mouse T-cell proliferation up to 30 μM.
Cell Proliferation Assay
| Cell Line: | Jurkat cells |
| Concentration: | 0 µM, 10 µM, 20 µM, 30 µM, 40 µM, 50 µM |
| Incubation Time: | 72 hours |
| Result: | In the presence of 10 µM dCuo, had a complete inhibitory effect for T-cell lines. |
Oral bioavailability of Peldesine in rats is 76%. Peldesine is orally active in elevating plasma inosine in rats (2-fold at 30 mg/kg), in suppressing ex vivo RBC PNP activity in rats (98% at 3 h. 100 mg/kg), and in suppressing ex vivo skin PNP in mice (39% at 3 h, 100 mg/kg).
Peldesine 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-106934 | 133432-71-0 | 1 mg | 1590 | |
| 2026-09-15 | HY-106934 | Peldesine | 133432-71-0 | 5mg | 3500 |
